This inventor holds 50 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 18 EPO patents, primarily in CGRP Antagonists (CPC class C07D). Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharma Gmbh & Co Kg, Orexo Ab. Active years: 2002-2016.
Inventors with similar research interests:
Location History:
- Birberach, DE (2002)
- Biberach, DE (2004 - 2015)
- Biberach an der Riss, DE (2013 - 2016)
Company Filing History:
35 out of 1,560 
8 out of 194 
4 out of 40 
Years Active: 2002-2016
Areas of Expertise:
Title: Innovator in Pharmaceutical Sciences: Dirk Stenkamp
Introduction
Dirk Stenkamp, a prominent inventor located in Biberach, Germany, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 50 patents, Stenkamp’s work focuses on developing innovative compounds that address critical health issues.
Latest Patents
One of Stenkamp's latest patents includes the development of 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives. These pharmaceutical compositions possess valuable pharmacological activity, particularly as agonists of the 5-HT2C receptor, making them suitable for treating and preventing diseases influenced by receptor inhibition, such as metabolic and CNS-related disorders. Additionally, his patent on 1H-benzimidazole-5-carboxamides highlights their potential as anti-inflammatory agents. These compounds aim to inhibit the activity of members of the MAPEG family, making them valuable in treating inflammation and cancer.
Career Highlights
Stenkamp has dedicated a substantial portion of his career to influential companies in the pharmaceutical industry. He has worked for Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG, where he has contributed to various innovative projects that underscore his expertise in drug development.
Collaborations
Throughout his career, Dirk Stenkamp has collaborated with notable professionals, including colleagues Klaus Rudolf and Stephan Georg Mueller. These partnerships have further enhanced the innovation and successful implementation of his ideas within the pharmaceutical landscape.
Conclusion
With his impressive number of patents and groundbreaking research, Dirk Stenkamp exemplifies the spirit of innovation in the pharmaceutical sector. His latest work continues to pave the way for advancements that may significantly impact the treatment of various health conditions. Stenkamp's dedication and collaborative spirit reflect the ongoing evolution of medical science and the importance of inventive contributions in this field.